Literature DB >> 18559790

Sorafenib-induced eruptive melanocytic lesions.

Heidi H Kong, Vincent Sibaud, Maria L Chanco Turner, Tito Fojo, Thomas J Hornyak, Christine Chevreau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18559790      PMCID： PMC2556207          DOI： 10.1001/archderm.144.6.820

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  6 in total

1.  The body site distribution of melanocytic naevi in 6-7 year old European children.

Authors:  P Autier; M Boniol; G Severi; G Giles; M S Cattaruzza; H Luther; F Renard; A R Grivegnée; R Pedeux; J F Doré
Journal:  Melanoma Res       Date:  2001-04       Impact factor: 3.599

Review 2.  Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals.

Authors:  H J Bovenschen; M Tjioe; H Vermaat; D de Hoop; B M J Witteman; R W A Janssens; T J Stoof; P C M van de Kerkhof
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

Review 3.  Chemotherapy and targeted therapy combinations in advanced melanoma.

Authors:  Keith T Flaherty
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

4.  Keratoacanthomas associated with sorafenib therapy.

Authors:  Heidi H Kong; Edward W Cowen; Nilofer S Azad; William Dahut; Martin Gutierrez; Maria L Turner
Journal:  J Am Acad Dermatol       Date:  2007-01       Impact factor: 11.527

5.  BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Authors:  Chrysiis Michaloglou; Liesbeth C W Vredeveld; Maria S Soengas; Christophe Denoyelle; Thomas Kuilman; Chantal M A M van der Horst; Donné M Majoor; Jerry W Shay; Wolter J Mooi; Daniel S Peeper
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

6.  Eruptive post-chemotherapy in situ melanomas and dysplastic nevi.

Authors:  Jason C Reutter; Erin M Long; Dean S Morrell; Nancy E Thomas; Pamela A Groben
Journal:  Pediatr Dermatol       Date:  2007 Mar-Apr       Impact factor: 1.588
  6 in total
  16 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

2.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Authors:  Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach
Journal:  J Am Acad Dermatol       Date:  2012-05-18       Impact factor: 11.527

3.  Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.

Authors:  Ji-chao Wei; Fan-di Meng; Kai Qu; Zhi-xin Wang; Qi-fei Wu; Ling-qiang Zhang; Qing Pang; Chang Liu
Journal:  Acta Pharmacol Sin       Date:  2015-01-05       Impact factor: 6.150

4.  Sorafenib-Induced Eruptive Melanocytic Lesions.

Authors:  Hui-Chun Chen; Sheau-Chiou Chao
Journal:  Indian J Dermatol       Date:  2021 Nov-Dec       Impact factor: 1.494

5.  Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.

Authors:  Philip R Cohen; Agop Y Bedikian; Kevin B Kim
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

6.  Array of cutaneous adverse effects associated with sorafenib.

Authors:  Heidi H Kong; Maria L Turner
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

7.  Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?

Authors:  V Sibaud; J P Delord; C Chevreau
Journal:  Target Oncol       Date:  2009-11-07       Impact factor: 4.493

Review 8.  Dermatological adverse events from BRAF inhibitors: a growing problem.

Authors:  Viswanath Reddy Belum; Alyssa Fischer; Jennifer Nam Choi; Mario E Lacouture
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

9.  Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Authors:  Marie Perier-Muzet; Luc Thomas; Nicolas Poulalhon; Sébastien Debarbieux; Pierre-Paul Bringuier; Gerard Duru; Lauriane Depaepe; Brigitte Balme; Stephane Dalle
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

10.  Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

Authors:  Alastair J King; Marc R Arnone; Maureen R Bleam; Katherine G Moss; Jingsong Yang; Kelly E Fedorowicz; Kimberly N Smitheman; Joseph A Erhardt; Angela Hughes-Earle; Laurie S Kane-Carson; Robert H Sinnamon; Hongwei Qi; Tara R Rheault; David E Uehling; Sylvie G Laquerre
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.